Premium
Effect of Significant Weight Change on Inappropriate Implantable Cardioverter‐Defibrillator Therapy
Author(s) -
DAIMEE USAMA A.,
BITON YITSCHAK,
AKTAS MEHMET K.,
ZANNAD FAIEZ,
KLEIN HELMUT,
SZEPIETOWSKA BARBARA,
MCNITT SCOTT,
POLONSKY BRONISLAVA,
WANG PAUL J.,
ZAREBA WOJCIECH,
MOSS ARTHUR J.,
KUTYIFA VALENTINA
Publication year - 2017
Publication title -
pacing and clinical electrophysiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.686
H-Index - 101
eISSN - 1540-8159
pISSN - 0147-8389
DOI - 10.1111/pace.12973
Subject(s) - medicine , cardiac resynchronization therapy , weight loss , weight change , weight gain , hazard ratio , cardiology , heart failure , implantable cardioverter defibrillator , clinical endpoint , confidence interval , adverse effect , clinical trial , body weight , obesity , ejection fraction
Background Weight loss has been associated with adverse outcomes among heart failure (HF) patients, including those receiving cardiac resynchronization therapy with defibrillator (CRT‐D). The effect of significant weight change on inappropriate implantable cardioverter‐defibrillator (ICD) therapy among CRT‐D patients is not well understood. Methods We evaluated the impact of significant weight change at 1 year on subsequent inappropriate ICD therapy during follow‐up among 993 CRT‐D patients enrolled in the Multicenter Automatic Defibrillator Implantation Trial‐Cardiac Resynchronization Therapy. Patients were divided into three subgroups based on weight change at 1 year after enrollment: weight loss (weight loss ≥ 5%), weight gain (weight gain ≥ 5%), and stable weight (weight loss and weight gain < 5%). The primary end point was inappropriate ICD therapy. Secondary end point included inappropriate ICD therapy related to supraventricular arrhythmias (SVAs). Results There were 102 (10.3%) patients who experienced weight loss, 689 (69.4%) whose weight was stable, and 202 (20.3%) who gained weight at 1 year. Patients with weight loss had increased risk of subsequent inappropriate ICD therapy relative to patients with stable weight (hazard ratio [HR] = 2.35, 95% confidence interval [CI]: 1.39–3.98, P = 0.001) or weight gain (HR = 2.27, 95% CI: 1.18–4.38, P = 0.014). Furthermore, patients losing weight were at greater risk of subsequent inappropriate ICD therapy related to SVAs when compared to patients with stable weight (HR = 2.16, 95% CI: 1.18–3.95, P = 0.013) or weight gain (HR = 2.02, 95% CI: 0.95–4.29, P = 0.068). Conclusion In mild HF patients receiving CRT‐D, significant weight loss at 1 year is associated with increased risk of subsequent inappropriate ICD therapy, including risk related to SVAs.